Adaptive Biotechnologies Corp. ($ADPT) reported second-quarter 2026 revenue of $71.6 million, up 21.5% from a year earlier and above the $67.2 million analyst estimate. Gross profit rose 25.7% year over year to $51.4 million, reflecting stronger top-line growth and improved product economics.
The company remained unprofitable, posting an operating loss of $15.8 million and a net loss attributable to common shareholders of $39.8 million. Diluted loss per share improved to $0.25 from the prior-year period, but still came in below breakeven.
On the cash side, operating activities used $9.5 million during the quarter, while capital spending was modest at $0.8 million. Adaptive ended the period with $169.9 million in cash and cash equivalents, while total liabilities stood at $490.0 million.
- Revenue: $71.6 million, up 21.5% year over year
- Gross profit: $51.4 million, up 25.7% year over year
- Net loss: $39.8 million
- Cash and equivalents: $169.9 million
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Adaptive Biotechnologies Corp. Insider Trading Activity
Adaptive Biotechnologies Corp. insiders have traded $ADPT stock on the open market 92 times in the past 6 months. Of those trades, 0 have been purchases and 92 have been sales.
Here’s a breakdown of recent trading of $ADPT stock by insiders over the last 6 months:
- HARLAN S ROBINS (Chief Scientific Officer) has made 0 purchases and 13 sales selling 1,532,087 shares for an estimated $28,662,836.
- CHAD M ROBINS (CEO and Chairman) has made 0 purchases and 9 sales selling 1,240,758 shares for an estimated $18,584,514.
- JULIE RUBINSTEIN (President and COO) has made 0 purchases and 47 sales selling 949,407 shares for an estimated $13,371,111.
- FRANCIS LO (Chief People Officer) has made 0 purchases and 8 sales selling 332,576 shares for an estimated $6,587,241.
- SHARON BENZENO (Chief Commercial Ofc Imm Med) has made 0 purchases and 3 sales selling 228,905 shares for an estimated $4,334,576.
- MICHELLE RENEE GRIFFIN has made 0 purchases and 3 sales selling 115,522 shares for an estimated $2,000,258.
- SUSAN BOBULSKY (Chief Commercial Officer, MRD) has made 0 purchases and 6 sales selling 67,825 shares for an estimated $1,065,635.
- KYLE PISKEL (Chief Financial Officer) has made 0 purchases and 3 sales selling 23,932 shares for an estimated $326,126.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Adaptive Biotechnologies Corp. Hedge Fund Activity
We have seen 133 institutional investors add shares of Adaptive Biotechnologies Corp. stock to their portfolio, and 122 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,821,148 shares (-64.3%) from their portfolio in Q1 2026, for an estimated $39,157,534
- BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. added 2,688,081 shares (+inf%) to their portfolio in Q1 2026, for an estimated $37,310,564
- JENNISON ASSOCIATES LLC removed 1,921,595 shares (-71.8%) from their portfolio in Q1 2026, for an estimated $26,671,738
- WELLINGTON MANAGEMENT GROUP LLP added 1,692,095 shares (+78.1%) to their portfolio in Q1 2026, for an estimated $23,486,278
- WESTFIELD CAPITAL MANAGEMENT CO LP added 1,376,237 shares (+33.9%) to their portfolio in Q1 2026, for an estimated $19,102,169
- CAPRICORN FUND MANAGERS LTD removed 1,269,080 shares (-98.2%) from their portfolio in Q2 2026, for an estimated $27,221,766
- DIMENSIONAL FUND ADVISORS LP removed 1,194,586 shares (-86.4%) from their portfolio in Q1 2026, for an estimated $16,580,853
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Adaptive Biotechnologies Corp. Government Contracts
We have seen $407,550 of award payments to $ADPT over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- CLONO-SEQ TESTING.: $243,750
- CLONOSEQ FDA-CLEARED IN VITRO DIAGNOSTIC (IVD) TESTING SERVICES: $128,700
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
Adaptive Biotechnologies Corp. Price Targets
Multiple analysts have issued price targets for $ADPT recently. We have seen 5 analysts offer price targets for $ADPT in the last 6 months, with a median target of $21.0.
Here are some recent targets:
- Tejas Savant from Morgan Stanley set a target price of $20.0 on 07/09/2026
- Subbu Nambi from Guggenheim set a target price of $22.0 on 06/29/2026
- Mark Massaro from BTIG set a target price of $22.0 on 06/17/2026
- Sebastian Sandler from JP Morgan set a target price of $19.0 on 05/06/2026
- Dan Brennan from TD Cowen set a target price of $21.0 on 05/06/2026
